Effects of medications on chronic pancreatitis in a rat model.

在WBN/KOB大鼠自发性慢性胰腺炎模型上，观察了口服蛋白水解酶抑制剂(卡莫司坦)对胰腺形态和外分泌功能的影响。在未经治疗的WBN/KOB大鼠(2~12月龄)中，胰腺纤维化和实质破坏与人类慢性胰腺炎相容，3个月时出现，并逐月进展。胰腺分泌在所有年龄段都明显受损。WBN/KOB大鼠饲喂含有卡莫司坦的饲料(2~3个月或4~5月龄)后，胰腺肥大，但没有表现出任何与慢性胰腺炎相容的组织学表现，而且随着血浆CCK浓度的增加，外分泌功能完全恢复。口服蛋白水解酶抑制剂对慢性胰腺炎动物模型中的胰腺损伤和功能障碍具有预防和治疗作用，可能是通过释放内源性胆囊收缩素实现的。

The effect of oral administration of protease inhibitor (camostat) on pancreatic morphology and exocrine function (conscious-rat model) was investigated using WBN/Kob rats with spontaneous chronic pancreatitis. In nontreated WBN/Kob rats (2 to 12 months of age), pancreatic fibrosis and parenchymal destruction compatible with human chronic pancreatitis appeared at 3 months and advanced with each month. Pancreatic secretion was markedly impaired at all ages. In WBN/Kob rats fed diets containing camostat (from 2 to 3, or from 4 to 5 months of age), the pancreas was hypertrophic but did not show any histological appearances compatible with chronic pancreatitis, and moreover, exocrine funciton was thoroughly restored with increased plasma cholecystokinin concentrations. Oral administration of protease inhibitor has both preventive and therapeutic effects on pancreatic lesions and dysfunction in an animal model of chronic pancreatitis, probably via endogenous cholecystokinin release.